As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Delaware 3690 85-1288435 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 7442 S Tucson Way, Suite 130 Centennial, CO 80112 (I.R.S. Employer Identification Number) Telephone: (720) 767-1400 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive ...

As filed with the Securities and Exchange Commission on August 22, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Table of Contents REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0927979 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 4275 E ...

Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 2834 Not Applicable (State or other jurisdiction of (Primary Standard Industrial Classification Code Number) As filed with the Securities and Exchange Commission on August 18, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION (I.R.S. Employer Identification Number) incorporation or organization) c/o ...

Core Viewpoint - FibroBiologics, Inc. has successfully closed the third $5 million tranche of a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing the company to raise up to $25 million over two years for its therapeutic development efforts [1][2]. Financing Details - The SEPA allows FibroBiologics to sell up to $25 million in common stock to Yorkville over two years, with the first three tranches totaling $15 million being advanced in equal parts of $5 million each [2]. - The third tranche of $5 million was funded after the effectiveness of a registration statement and shareholder approval, complying with Nasdaq rules [2]. Use of Proceeds - The net proceeds from this financing are intended for general corporate purposes, including funding research and development programs and supporting an upcoming Phase 1/2 clinical trial for diabetic foot ulcers expected to start in the second half of 2025 [3]. Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials [7][8]. - The company holds over 275 patents issued and pending, covering various clinical pathways such as wound healing, multiple sclerosis, and cancer [8].

Core Viewpoint - Scinai Immunotherapeutics Ltd. has entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing the company to sell up to $10 million of its American Depository Shares (ADSs) over a three-year period to support its R&D and CDMO business expansion [1][2][5]. Group 1: SEPA Details - The SEPA allows Scinai to sell ADSs at a 3% discount to the lowest daily volume-weighted average price over three consecutive trading days following an advance notice [3]. - Scinai retains full control over the timing and amount of sales under the SEPA, with no obligation to utilize the full $10 million [4]. - The agreement includes a beneficial ownership cap of 9.99% of Scinai's share capital at any one time, along with other restrictions [2]. Group 2: Use of Proceeds - Proceeds from the potential offering of ADSs under the SEPA will be used to further develop NanoAbs programs, support the CDMO business, and for general corporate purposes including working capital and regulatory matters [5]. Group 3: Company Overview - Scinai Immunotherapeutics is focused on developing inflammation and immunology biological products and offers CDMO services through its Scinai Bioservices unit [1][7]. - The company has a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with significant unmet medical needs [7].

As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. 333-282559 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLUNA HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 7374 14-1462255 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Nu ...

As filed with the Securities and Exchange Commission on August 30, 2024. Washington, DC 20549 Registration No. 333- FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALMED PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION State of Israel 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) c/o ...

As filed with the Securities and Exchange Commission on August 13, 2024 Registration No. 333-280863 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GameSquare Holdings, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 7900 99-1946435 (Primary Standard Industrial Classification Code No.) (I.R.S. Employer Identification No.) ...

As filed with the Securities and Exchange Commission on October 12, 2023. REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sadot Group Inc. (Exact Name of Registrant as Specified in its Charter) incorporation or organization Classification Code Number) Identification Number) Registration No. 333-______ Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM S-1 Nevada 5810 47-2555533 State or other jurisdiction (Primary Standard Industrial (I.R.S. Employer 1751 River Run, Suite 2 ...